{"entity":{"id":"nct06319963","kind":"trial","name":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","aka":[],"tldr":"A phase 1/2 trial of Two IM injections Lenti-HPV-07 in cervical cancer and head and neck squamous cell carcinoma, run by Theravectys S.A., now recruiting.","summary":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer is a phase 1/2 interventional study registered as NCT06319963 by Theravectys S.A., with 72 participants planned, started 2024-08-08 and due to reach its primary completion in 2026-06. Interventions recorded: Two IM injections Lenti-HPV-07 and One IM injection Lenti-HPV-07.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06319963","url":"https://clinicaltrials.gov/study/NCT06319963"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06319963","phase":"1/2","setting":"An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer","sponsor":"Theravectys S.A.","enrolled":72,"outcomes":[]},"route":"/trials/nct06319963/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}]}}